{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-24-000207","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.874171+00:00","generated_at":"2026-06-01T00:19:24.541076+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Artivion provides $25M additional loans to Endospan, reduces purchase option to $135M net","bullets":["Up to $25M in three tranches ($7M upfront) to fund NEXUS FDA approval; loan secured by first-priority lien.","Purchase option upfront payment reduced from $250M to $175M; net to $135M after loan offset.","$100M minimum earnout eliminated; earnout now 2.5x incremental year-2 revenue (max $200M).","Company does not expect material impact on FY2024 guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-24-000207","json":"https://secwatch.observer/filing/0000784199-24-000207.json","markdown":"https://secwatch.observer/filing/0000784199-24-000207.md","text":"https://secwatch.observer/filing/0000784199-24-000207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419924000207/0000784199-24-000207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419924000207/aort-20240701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:19:24.541076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}